Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Naoqingzhiming Tablets in Healthy Subjects
NCT04902534Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Naoqingzhiming Tablets with Placebo (2 arms). Primary endpoints: Maximum tolerated dose at 500 days and Occurrence rate of Adverse Events at 500 days. Status: unknown.
02
Drugs
echinacoside
Beyond the preview
Go deeper on NCT04902534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902534.